Colin Love PhD

Colin Love most recently provided consultancy support to a range of companies from small gene therapy start-ups to large established biotech companies. He has over 30 years experience developing and launching biotechnology products and led development teams for Medeva, Serono and Amersham, prior to joining BioVex. Colin was SVP of Product Development at BioVex from 2000 until it was acquired by Amgen in 2011. Following the acquisition, he remained at Amgen as VP of R&D Operations working on T-VEC until it was approved in 2015.